Business
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
Effective as of Commencement of Trading on August 15, 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Therapeutics, Inc., a clinical-stage healthcare company
About this update from Vyome Holdings, Inc.
[{"type":"text","content":"\nEffective as of Commencement of Trading on August 15, 2025\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nVyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.”\n\n\n“Nasdaq’s approval is right on track and now we are marching forward to ring the bell on our planned listing date this Friday. We look forward to welcoming RSLS shareholders and invite all others who wish to be part of our journey, which I promise will at all times be focused only on shareholder value. If you believe in the global healthcare market, in the opportunities to do business between the US and India, and in the value of a group of smart people driving real innovation across science and AI, you believe in Vyome,” said Krishna Gupta, Chairman of Vyome.\n\n\n“Inflammation is one of the most impactful chronic conditions afflicting humanity today. There are a large number of inflammatory diseases, a market exceeding over $100B, and all connected to our immune system not functioning as it should. Vyome’s existing, clinical stage assets – developed over years of work – are focused on major unmet indications in this immuno-inflammatory space,” said Shiladitya Sengupta, founder of Vyome and Associate Professor of Medicine at Harvard Medical School.\n\n\nIn connection with the expected completion of the merger and Nasdaq requirements, ReShape’s Board of Directors has declared a 1-for-4 reverse stock split of the company’s common stock, which will also be effective for marketplace purposes upon the commencement of trading on August 15, 2025. At that time, each four shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. The new CUSIP number for the company’s common stock following the reverse stock split and merger will be 92943X104. The reverse split does not impact the post-merger ownership allocations between the ReShape and Vyome shareholders in the deal.\...